Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals

被引:3
作者
Chapel, Cynthia [1 ]
Zitzmann, Nicole [1 ]
Zoulim, Fabien [1 ]
Durantel, David [1 ]
机构
[1] INSERM, Lab Virus Hepatiques Pathol Assoc, F-69424 Lyon, France
关键词
alpha-glucosidase inhibitors; antivirals; assembly; glycoproteins; hepatitis C virus; iminosugars; morphogenesis; viral entry;
D O I
10.2217/17460794.1.2.197
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis C virus (HCV) infection is a major public health concern. New antiviral drugs are required urgently to complement and improve the efficacy of current chemotherapies. Molecules specifically targeting viral enzymes are the most attractive in terms of drug development and are, therefore, the most studied. However, an antiviral strategy based uniquely on the utilization of this type of target is expected to encounter problems caused by the emergence of viral escape mutants as has already been widely described for HIV and hepatitis B virus. HCV morphogenesis and viral entry represent interesting, and yet unexploited, novel molecular targets. Inhibitors of morphogenesis have recently been identified and studied in different virus-cell systems. Some of these are currently being evaluated in clinical trials against HCV This review focuses on HCV morphogenesis, viral entry and inhibition and presents clinical development perspectives of this new generation of antivirals.
引用
收藏
页码:197 / 209
页数:13
相关论文
共 72 条
[1]   Characterization of low- and very-low-density hepatitis C virus RNA-containing particles [J].
André, P ;
Komurian-Pradel, F ;
Deforges, S ;
Perret, M ;
Berland, JL ;
Sodoyer, M ;
Pol, S ;
Bréchot, C ;
Paranhos-Baccalà, G ;
Lotteau, V .
JOURNAL OF VIROLOGY, 2002, 76 (14) :6919-6928
[2]   Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor [J].
Bartosch, B ;
Vitelli, A ;
Granier, C ;
Goujon, C ;
Dubuisson, J ;
Pascale, S ;
Scarselli, E ;
Cortese, R ;
Nicosia, A ;
Cosset, FL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) :41624-41630
[3]   In vitro assay for neutralizing antibody to hepatitis C virus:: Evidence for broadly conserved neutralization epitopes [J].
Bartosch, B ;
Bukh, J ;
Meunier, JC ;
Granier, C ;
Engle, RE ;
Blackwelder, WC ;
Emerson, SU ;
Cosset, FL ;
Purcell, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :14199-14204
[4]   Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes [J].
Bartosch, B ;
Dubuisson, J ;
Cosset, FL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (05) :633-642
[5]   Hepatitis C virus structural proteins assemble into viruslike particles in insect cells [J].
Baumert, TF ;
Ito, S ;
Wong, DT ;
Liang, TJ .
JOURNAL OF VIROLOGY, 1998, 72 (05) :3827-3836
[6]   Hepatitis C virus-like particle morphogenesis [J].
Blanchard, E ;
Brand, D ;
Trassard, S ;
Goudeau, A ;
Roingeard, P .
JOURNAL OF VIROLOGY, 2002, 76 (08) :4073-4079
[7]   Folding of viral envelope glycoproteins in the endoplasmic reticulum [J].
Braakman, I ;
van Anken, E .
TRAFFIC, 2000, 1 (07) :533-539
[8]   Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers [J].
Branza-Nichita, N ;
Durantel, D ;
Carrouée-Durantel, S ;
Dwek, RA ;
Zitzmann, N .
JOURNAL OF VIROLOGY, 2001, 75 (08) :3527-3536
[9]   Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells [J].
Brazzoli, M ;
Helenius, A ;
Foung, SKH ;
Houghton, M ;
Abrignani, S ;
Merola, M .
VIROLOGY, 2005, 332 (01) :438-453
[10]   Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins [J].
Buonocore, L ;
Blight, KJ ;
Rice, CM ;
Rose, JK .
JOURNAL OF VIROLOGY, 2002, 76 (14) :6865-6872